Clinicopathological significance of mesothelin expression in invasive breast cancer

Journal of International Medical Research

Volumn 40, Issue 3, 2012, Pages 909-916

  Wang, L ^a   Niu, Z ^a   Zhang, L ^a   Liu, X ^b   Wang, X ^b   Li, F ^b   Wang, Yu ^b  

^a Tianjin Union Medicine Centre   (China)

^b QINGDAO UNIVERSITY   (China)

Author keywords

Breast cancer; Lymph node; Mesothelin; Metastasis; Mhuman epidermal growth factor receptor 2 (HER2 neu); Oestrogen Receptor; Overall survival; Progesterone receptor

Indexed keywords

CYCLOPHOSPHAMIDE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUOROURACIL; MESOTHELIN; METHOTREXATE; PROGESTERONE RECEPTOR; TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; COHORT ANALYSIS; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GENE EXPRESSION PROFILING; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MSLN GENE; MULTIPLE CYCLE TREATMENT; ONCOGENE; OVERALL SURVIVAL; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; TUMOR VOLUME;

EID: 84863114224     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323001204000309     Document Type: Article

References (25)

1. Vivanco M: Biomarkers in breast cancer. Methods Mol Biol 2010; 593: 137-156.
2. Yu KD, Di GH, Wu J, et al: Development and trends of surgical modalities for breast cancer in China: a review of 16-year data. Ann Surg Oncol 2007; 14: 2502-2509.
3. Maskarinec G, Sen C, Koga K, et al: Ethnic differences in breast cancer survival: status and determinants. Womens Health (Lond Engl) 2011; 7: 677-687.
4. Chang K, Pastan I: Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci U S A 1996; 93: 136-140.
5. Chang K, Pastan I, Willingham MC: Isolation and characterization of a monoclonal antibody, K1, reactive with ovarian cancers and normal mesothelium. Int J Cancer 1992; 50: 373-381.
6. Rump A, Morikawa Y, Tanaka M, et al: Binding of ovarian cancer antigen CA125/MUC16 to mesothelin mediates cell adhesion. J Biol Chem 2004; 279: 9190-9198.
7. Hassan R, Laszik ZG, Lerner M, et al: Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005; 124: 838-845.
8. Argani P, Iacobuzio-Donahue C, Ryu B, et al: Mesothelin is overexpressed in the vast majority of ductal adenocarcinomas of the pancreas: identification of a new pancreatic cancer marker by serial analysis of gene expression (SAGE). Clin Cancer Res 2001; 7: 3862-3868.
9. Uehara N, Matsuoka Y, Tsubura A: Mesothelin promotes anchorage-independent growth and prevents anoikis via extracellular signalregulated kinase signaling pathway in human breast cancer cells. Mol Cancer Res 2008; 6: 186-193.
10. Francis G, Beadle G, Thomas S, et al: Evaluation of oestrogen and progesterone receptor status in HER-2 positive breast carcinomas and correlation with outcome. Pathology 2006; 38: 391-398.
11. Ménard S, Fortis S, Castiglioni F, et al: HER2 as a prognostic factor in breast cancer. Oncology 2001; 61(suppl 2): 67-72.
12. Guarneri V, Giovannelli S, Ficarra G, et al: Comparison of HER-2 and hormone receptor expression in primary breast cancers and asynchronous paired metastases: impact on patient management. Oncologist 2008; 13: 838-844.
13. Ivkovic-Kapicl T, Knezevic-Usaj S, Djilas-Ivanovic D, et al: Correlation of HER-2/neu protein overexpression with other prognostic and predictive factors in invasive ductal breast cancer. In Vivo 2007; 21: 673-678.
14. Ordóñez NG: Value of mesothelin immunostaining in the diagnosis of mesothelioma. Mod Pathol 2003; 16: 192-197.
15. Hassan R, Kreitman RJ, Pastan I, et al: Localization of mesothelin in epithelial ovarian cancer. Appl Immunohistochem Mol Morphol 2005; 13: 243-247.
16. Ordóñez NG: Application of mesothelin immunostaining in tumor diagnosis. Am J Surg Pathol 2003; 27: 1418-1428.
17. Rizk NP, Servais EL, Tang LH, et al: Tissue and serum mesothelin are potential markers of neoplastic progression in Barrett's associated esophageal adenocarcinoma. Cancer Epidemiol Biomarkers Prev 2012; 21: 482-486.
18. Bera TK, Pastan I: Mesothelin is not required for normal mouse development or reproduction. Mol Cell Biol 2000; 20: 2902-2906.
19. Yen MJ, Hsu CY, Mao TL, et al: Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res 2006; 12: 827-831.
20. Baba K, Ishigami S, Arigami T, et al: Mesothelin expression correlates with prolonged patient survival in gastric cancer. J Surg Oncol 2012; 105: 195-199.
21. Galloway ML, Murray D, Moffat DF: The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies. Histopathology 2006; 48: 767-769.
22. Gubbels JA, Belisle J, Onda M, et al: Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors. Mol Cancer 2006; 5: 50.
23. Prieve MG, Moon RT: Stromelysin-1 and mesothelin are differentially regulated by Wnt-5a and Wnt-1 in C57mg mouse mammary epithelial cells. BMC Dev Biol 2003; 3: 2.
24. Ciocca DR, Gago FE, Fanelli MA, et al: Coexpression of steroid receptors (estrogen receptor alpha and/or progesterone receptors) and Her-2/neu: Clinical implications. J Steroid Biochem Mol Biol 2006; 102: 32-40.
25. Cao W, Zhang B, Liu Y: High-level SLP-2 expression and HER2/neu protein expression are associated with decreased breast cancer patient survival. Am J Clin Pathol 2007; 128: 430-436.